Tag - LBRX

Markets

Clear Street starts LB Pharmaceuticals at buy; PT $45

Clear Street initiated coverage of LB Pharmaceuticals (NASDAQ: LBRX) with a “buy” rating and price target of $45.00. The stock closed at $28.33 on May 26th. LB Pharmaceuticals is a late-stage biopharmaceutical company...

May 26, 2026

Executive Moves

James Rawls, PharmD, joins LB as SVP of regulatory affairs

LB Pharmaceuticals (NASDAQ: LBRX) has announced the appointment of James Rawls, PharmD, as senior vice president (SVP) of regulatory affairs. With more than 25 years of regulatory leadership experience across global...

October 14, 2025

Tag - LBRX

Clear Street starts LB Pharmaceuticals at buy; PT $45

James Rawls, PharmD, joins LB as SVP of regulatory affairs

Subscribe